Detailed description page of THPdb

This page displays user query in tabular form.

Th1071 details

Primary information
ID 1422
ThPP ID Th1071
Therapeutic Peptide/Protein Name Pancrelipase
Sequence Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification Ia
Molecular Weight 131125.6
Chemical Formula C5850H8902N1606O1739S49
Isoelectric Point 6.44
Hydrophobicity N.A.
Melting Point (℃) 48-50
Half Life Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism Pancrelipase acts locally, so there is minimal metabolism.
Absorption Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution N.A.
Clearance Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction If pancrelipase and iron salts are used in combination then monitor therapy. Pancrelipase may decrease the absorption of iron salts except for ferumoxytol, iron dextran complex, and iron sucrose
Target N.A.
Information of corresponding available drug in the market
Brand Name Pancrecarb
Company Digestive care US, Inc.
Brand Discription PANCRECARB (pancrelipase) contain buffered pancreatic enzymes: lipase,amylaseÂ andÂ protease, isolated and concentrated from porcine pancreatic glands. The enzyme containing microspheres are coated with a pH sensitive enteric-coating to provide protection against gastric inactivation of the buffer-stabilized enzymes during gastric passage.
Prescribed for PANCRECARB (pancrelipase) Delayed-Release Capsules, Buffered andEnteric-CoatedÂ Microspheres are indicated for patients withÂ exocrinepancreaticÂ enzymeÂ insufficiency such as:Â cystic fibrosis,Â chronic pancreatitisdue to alcohol use or other causes, post-pancreatectomy and post-gastrointestinalÂ bypassÂ surgeryÂ
Chemical Name N.A.
Formulation it is formulated as Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres.It contains Lipase :4000 to 8000 U.S.P. units, Amylase: 25000 to 40000 U.S.P. units, Protease: 25000 to 45000 U.S.P. units.nactive ingredients include sodium carbonate, sodium bicarbonate, cellulose acetate phthalate, diethyl phthalate, gelatin, sodium carboxymethyl starch, polyvinylpyrrolidone, talc, ursodiol, and other trace ingredients.
Physcial Appearance Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres.
Route of Administration Oral route
Recommended Dosage Dosage should be individualized and adjusted according to fat intake, severity of steatorrhea and the severity of the exocrineÂ pancreatic insufficiency. Begin therapy with one or two capsules with meals or snacks and adjust dosage according to symptoms.
Contraindication PANCRECARB (pancrelipase) Delayed-Release Capsules, Buffered andEnteric-CoatedÂ Microspheres are contraindicated in patients known to be hypersensitive to porkÂ proteinÂ or any other ingredient of this product.
Side Effects The most frequently reported adverse reactions to pancrelipase-containing products areÂ gastrointestinalÂ inÂ nature, which may includeÂ nausea, vomiting, bloating, cramping, constipation orÂ diarrhea. Less frequently, allergic-type reactions have also been observed. Extremely high doses ofÂ exogenouspancreaticÂ enzymesÂ have been reported to be associated with hyperuricosuria andÂ hyperuricemia. High strength pancrelipase preparation (i.e., those labeled as containing more than 20,000 lipase units perÂ capsule) has been associated withÂ colonicÂ strictures.
Useful Link http://www.rxlist.com/pancrecarb-drug.htm
PubMed ID 28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure Th1071 (View) or (Download)

Primary information
ID 1423
ThPP ID Th1071
Therapeutic Peptide/Protein Name Pancrelipase
Sequence Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification Ia
Molecular Weight 131125.6
Chemical Formula C5850H8902N1606O1739S49
Isoelectric Point 7.44
Hydrophobicity N.A.
Melting Point (℃) 48-51
Half Life Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism Pancrelipase acts locally, so there is minimal metabolism.
Absorption Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution N.A.
Clearance Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Viokace
Company Aptalis Pharma US, Inc.
Brand Discription VIOKACE is a pancreatic enzyme preparation for oral administration consisting of pancrelipase, an extract derived fromÂ porcineÂ pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, amylases, and proteases.
Prescribed for VIOKACE (pancrelipase) tablets, in combination with a proton pump inhibitor, is indicated in adults for the treatment ofÂ exocrineÂ paencratic insufficiencydue toÂ chronic pancreatitisÂ orÂ pancreatectomy.
Chemical Name N.A.
Formulation 10,440 USP units of lipase;Â 39,150 USP units of protease; 39,150 USP units of amylase tablets are tan, round biconvex and have VIO9111 engraved on one side and 9111 on the other side.Inactive ingredients in VIOKACE include: colloidal silicon dioxide, crosscarmellose sodium, lactose monohydrate, microcrystalline cellulose, stearic acid and talc.
Physcial Appearance Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble in alcohol and converted to tablet form
Route of Administration Oral route
Recommended Dosage Enzyme dosing should begin with 500 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Contraindication None
Side Effects The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy, hyperuricemiaÂ and allergic reactions.
Useful Link http://www.rxlist.com/viokace-drug.htm
PubMed ID 28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure Th1071 (View) or (Download)

Primary information
ID 1424
ThPP ID Th1071
Therapeutic Peptide/Protein Name Pancrelipase
Sequence Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification Ia
Molecular Weight 131125.6
Chemical Formula C5850H8902N1606O1739S49
Isoelectric Point 8.44
Hydrophobicity N.A.
Melting Point (℃) 48-52
Half Life Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism Pancrelipase acts locally, so there is minimal metabolism.
Absorption Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution N.A.
Clearance Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB
Information of corresponding available drug in the market
Brand Name ULTRESA
Company Aptalis Pharma US, Inc.
Brand Discription ULTRESA is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived fromÂ porcineÂ pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, amylases, and proteases.
Prescribed for ULTRESA (pancrelipase) is indicated for the treatment of exocrinepancreatic insufficiencyÂ due to cystic fibrosis or other conditions.
Chemical Name N.A.
Formulation Each delayed-release capsule for oral administration containsÂ enteric-coatedbeads (1.7 mm in diameter and 1.9 mm thick for 4,000 USP lipase units, approximately 2.0 mm in diameter and 2.0 â€“ 2.4 mm thick for 13,800, 20,700, and 23,000 USP lipase units). it also contains colloidal silicon dioxide, croscarmellose sodium, hydrogenated castor oil, hypromellose phthalate, magnesium stearate, microcrystalline cellulose, talc, and triethyl citrate.
Physcial Appearance Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble or insoluble in alcohol and ether and converted to Delayed-Release Capsules
Route of Administration Oral route
Recommended Dosage Enzyme dosing should begin with 500 lipase units/kg of body weight per meal for those older than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Contraindication None
Side Effects The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy,hyperuricemiaÂ and allergic reactions.
Useful Link http://www.rxlist.com/ultresa-drug.htm
PubMed ID 28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure Th1071 (View) or (Download)

Primary information
ID 1425
ThPP ID Th1071
Therapeutic Peptide/Protein Name Pancrelipase
Sequence Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification Ia
Molecular Weight 131125.6
Chemical Formula C5850H8902N1606O1739S49
Isoelectric Point 9.44
Hydrophobicity N.A.
Melting Point (℃) 48-53
Half Life Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism Pancrelipase acts locally, so there is minimal metabolism.
Absorption Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution N.A.
Clearance Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name PERTZYE
Company Digestive care US, Inc.
Brand Discription PERTZYE is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived fromÂ porcineÂ pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, proteases, and amylases.
Prescribed for PERTZYE (pancrelipase) is indicated for the treatment of exocrinepancreatic insufficiencyÂ due toÂ cystic fibrosisÂ or other conditions.
Chemical Name N.A.
Formulation Each PERTZYE delayed-release capsule for oral administration contains bicarbonatebufferedÂ enteric-coatedÂ microspheres ranging in size from 0.8 â€“ 2.2 mm in diameter.8,000 USP units of lipase; 28,750 USP units of protease; 30,250 USP units of amylase. it also contains odium bicarbonate, sodium carbonate, cellulose acetate phthalate, sodium starch glycolate, diethyl phthalate, ursodiol, polyvinylpyrrolidone, and talc and are contained in hard gelatin capsules.
Physcial Appearance Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble or insoluble in alcohol and ether PERTZYE delayed-release capsule
Route of Administration Oral route
Recommended Dosage Enzyme dosing should begin with 500 lipase units/kg of body weight per meal for those older than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Contraindication None
Side Effects The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy,hyperuricemiaÂ and allergic reactions
Useful Link http://www.rxlist.com/pertzye-drug.htm
PubMed ID 28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure Th1071 (View) or (Download)

Primary information
ID 1426
ThPP ID Th1071
Therapeutic Peptide/Protein Name Pancrelipase
Sequence Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification Ia
Molecular Weight 131125.6
Chemical Formula C5850H8902N1606O1739S49
Isoelectric Point 10.44
Hydrophobicity N.A.
Melting Point (℃) 48-54
Half Life Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism Pancrelipase acts locally, so there is minimal metabolism.
Absorption Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution N.A.
Clearance Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name ULTRASE
Company Axcan Pharma
Brand Discription ULTRASE (pancrelipase) Capsules are orally administered and contain 250 mg of enteric-coated microspheres ofÂ porcineÂ pancreaticÂ enzymeconcentrate, predominantly pancreatic lipase,Â amylase, andÂ protease.
Prescribed for ULTRASE (pancrelipase) Capsules are indicated for patients with partial or complete exocrine pancreatic insufficiency caused by cystic fibrosis, Chronic pancreatitis due to alcohol, Obstruction, Other pancreatic disease, Poor mixing
Chemical Name N.A.
Formulation Each ULTRASE (pancrelipase) Capsule contains 4500 USP units of lipase; 25000 USP units of protease; 20000 USP units of amylase. It contains povidone, talc, sugar, methacrylic acid copolymer (Type C), triethyl citrate, simethicone emulsion.
Physcial Appearance Capsules Enteric-Coated Microspheres
Route of Administration Oral route
Recommended Dosage Initial dosing of pancreatic enzyme supplements should begin with 500 lipase U/kg/meal using enteric-coated microsphere products.
Contraindication Pancrelipase capsules are contraindicated in patients known to be hypersensitive to porkÂ protein. Pancrelipase capsules are contraindicated in patients withÂ acute pancreatitisÂ or withÂ acuteÂ exacerbations ofÂ chronicpancreaticÂ diseases.
Side Effects Â Extremely high doses ofÂ exogenouspancreaticÂ enzymesÂ have been associated with hyperuricosuria andhyperuricemia,
Useful Link http://www.rxlist.com/ultrase-drug.htm
PubMed ID 28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure Th1071 (View) or (Download)

Primary information
ID 1427
ThPP ID Th1071
Therapeutic Peptide/Protein Name Pancrelipase
Sequence Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification Ia
Molecular Weight 131125.6
Chemical Formula C5850H8902N1606O1739S49
Isoelectric Point 11.44
Hydrophobicity N.A.
Melting Point (℃) 48-55
Half Life Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism Pancrelipase acts locally, so there is minimal metabolism.
Absorption Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution N.A.
Clearance Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Dietary fat,Dietary protein,Dietary starch
Information of corresponding available drug in the market
Brand Name ZENPEP
Company Aptalis Pharma US, Inc.
Brand Discription ZENPEP is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived fromÂ porcineÂ pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, proteases, and amylases.
Prescribed for ZENPEP (pancrelipase) is indicated for the treatment of exocrinepancreatic insufficiencyÂ due toÂ cystic fibrosisÂ or other conditions.
Chemical Name N.A.
Formulation Each capsule for oral administration containsÂ enteric-coatedÂ beads (1.8-1.9mm for 3,000 and 5,000 USP units of lipase, 2.2-2.5mm for 10,000, 15,000, 20,000, 25,000, and 40,000 USP units of lipase). ZENPEP include colloidal silicon dioxide, croscarmellose sodium, hydrogenated castor oil, hypromellose phthalate, magnesium stearate, microcrystalline cellulose, talc, and triethyl citrate and are contained in hypromellose capsules. The imprinting red ink on the 3,000 capsules strength contains, antifoam DC 1510, industrial methylated spirit, iron oxide red C.I. 77491-E172, n-butyl alcohol, shellac and soya lecithin.
Physcial Appearance Delayed-Release Capsules
Route of Administration Oral route
Recommended Dosage Enzyme dosing should begin with 500 lipase units/kg of body weight per meal for those older than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Contraindication None
Side Effects The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy,hyperuricemiaÂ and allergic reactions
Useful Link http://www.rxlist.com/zenpep-drug.htm
PubMed ID 28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure Th1071 (View) or (Download)

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

Primary information
ID	1422
ThPP ID	Th1071
Therapeutic Peptide/Protein Name	Pancrelipase
Sequence	Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	131125.6
Chemical Formula	C5850H8902N1606O1739S49
Isoelectric Point	6.44
Hydrophobicity	N.A.
Melting Point (℃)	48-50
Half Life	Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description	Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease	For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics	Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action	The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity	Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism	Pancrelipase acts locally, so there is minimal metabolism.
Absorption	Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution	N.A.
Clearance	Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories	Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	If pancrelipase and iron salts are used in combination then monitor therapy. Pancrelipase may decrease the absorption of iron salts except for ferumoxytol, iron dextran complex, and iron sucrose
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Pancrecarb
Company	Digestive care US, Inc.
Brand Discription	PANCRECARB (pancrelipase) contain buffered pancreatic enzymes: lipase,amylaseÂ andÂ protease, isolated and concentrated from porcine pancreatic glands. The enzyme containing microspheres are coated with a pH sensitive enteric-coating to provide protection against gastric inactivation of the buffer-stabilized enzymes during gastric passage.
Prescribed for	PANCRECARB (pancrelipase) Delayed-Release Capsules, Buffered andEnteric-CoatedÂ Microspheres are indicated for patients withÂ exocrinepancreaticÂ enzymeÂ insufficiency such as:Â cystic fibrosis,Â chronic pancreatitisdue to alcohol use or other causes, post-pancreatectomy and post-gastrointestinalÂ bypassÂ surgeryÂ
Chemical Name	N.A.
Formulation	it is formulated as Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres.It contains Lipase :4000 to 8000 U.S.P. units, Amylase: 25000 to 40000 U.S.P. units, Protease: 25000 to 45000 U.S.P. units.nactive ingredients include sodium carbonate, sodium bicarbonate, cellulose acetate phthalate, diethyl phthalate, gelatin, sodium carboxymethyl starch, polyvinylpyrrolidone, talc, ursodiol, and other trace ingredients.
Physcial Appearance	Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres.
Route of Administration	Oral route
Recommended Dosage	Dosage should be individualized and adjusted according to fat intake, severity of steatorrhea and the severity of the exocrineÂ pancreatic insufficiency. Begin therapy with one or two capsules with meals or snacks and adjust dosage according to symptoms.
Contraindication	PANCRECARB (pancrelipase) Delayed-Release Capsules, Buffered andEnteric-CoatedÂ Microspheres are contraindicated in patients known to be hypersensitive to porkÂ proteinÂ or any other ingredient of this product.
Side Effects	The most frequently reported adverse reactions to pancrelipase-containing products areÂ gastrointestinalÂ inÂ nature, which may includeÂ nausea, vomiting, bloating, cramping, constipation orÂ diarrhea. Less frequently, allergic-type reactions have also been observed. Extremely high doses ofÂ exogenouspancreaticÂ enzymesÂ have been reported to be associated with hyperuricosuria andÂ hyperuricemia. High strength pancrelipase preparation (i.e., those labeled as containing more than 20,000 lipase units perÂ capsule) has been associated withÂ colonicÂ strictures.
Useful Link	http://www.rxlist.com/pancrecarb-drug.htm
PubMed ID	28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure	Th1071 (View) or (Download)

Primary information
ID	1423
ThPP ID	Th1071
Therapeutic Peptide/Protein Name	Pancrelipase
Sequence	Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	131125.6
Chemical Formula	C5850H8902N1606O1739S49
Isoelectric Point	7.44
Hydrophobicity	N.A.
Melting Point (℃)	48-51
Half Life	Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description	Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease	For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics	Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action	The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity	Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism	Pancrelipase acts locally, so there is minimal metabolism.
Absorption	Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution	N.A.
Clearance	Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories	Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Viokace
Company	Aptalis Pharma US, Inc.
Brand Discription	VIOKACE is a pancreatic enzyme preparation for oral administration consisting of pancrelipase, an extract derived fromÂ porcineÂ pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, amylases, and proteases.
Prescribed for	VIOKACE (pancrelipase) tablets, in combination with a proton pump inhibitor, is indicated in adults for the treatment ofÂ exocrineÂ paencratic insufficiencydue toÂ chronic pancreatitisÂ orÂ pancreatectomy.
Chemical Name	N.A.
Formulation	10,440 USP units of lipase;Â 39,150 USP units of protease; 39,150 USP units of amylase tablets are tan, round biconvex and have VIO9111 engraved on one side and 9111 on the other side.Inactive ingredients in VIOKACE include: colloidal silicon dioxide, crosscarmellose sodium, lactose monohydrate, microcrystalline cellulose, stearic acid and talc.
Physcial Appearance	Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble in alcohol and converted to tablet form
Route of Administration	Oral route
Recommended Dosage	Enzyme dosing should begin with 500 lipase units/kg of body weight per meal to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Contraindication	None
Side Effects	The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy, hyperuricemiaÂ and allergic reactions.
Useful Link	http://www.rxlist.com/viokace-drug.htm
PubMed ID	28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure	Th1071 (View) or (Download)

Primary information
ID	1424
ThPP ID	Th1071
Therapeutic Peptide/Protein Name	Pancrelipase
Sequence	Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	131125.6
Chemical Formula	C5850H8902N1606O1739S49
Isoelectric Point	8.44
Hydrophobicity	N.A.
Melting Point (℃)	48-52
Half Life	Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description	Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease	For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics	Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action	The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity	Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism	Pancrelipase acts locally, so there is minimal metabolism.
Absorption	Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution	N.A.
Clearance	Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories	Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB
Information of corresponding available drug in the market
Brand Name	ULTRESA
Company	Aptalis Pharma US, Inc.
Brand Discription	ULTRESA is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived fromÂ porcineÂ pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, amylases, and proteases.
Prescribed for	ULTRESA (pancrelipase) is indicated for the treatment of exocrinepancreatic insufficiencyÂ due to cystic fibrosis or other conditions.
Chemical Name	N.A.
Formulation	Each delayed-release capsule for oral administration containsÂ enteric-coatedbeads (1.7 mm in diameter and 1.9 mm thick for 4,000 USP lipase units, approximately 2.0 mm in diameter and 2.0 â€“ 2.4 mm thick for 13,800, 20,700, and 23,000 USP lipase units). it also contains colloidal silicon dioxide, croscarmellose sodium, hydrogenated castor oil, hypromellose phthalate, magnesium stearate, microcrystalline cellulose, talc, and triethyl citrate.
Physcial Appearance	Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble or insoluble in alcohol and ether and converted to Delayed-Release Capsules
Route of Administration	Oral route
Recommended Dosage	Enzyme dosing should begin with 500 lipase units/kg of body weight per meal for those older than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Contraindication	None
Side Effects	The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy,hyperuricemiaÂ and allergic reactions.
Useful Link	http://www.rxlist.com/ultresa-drug.htm
PubMed ID	28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure	Th1071 (View) or (Download)

Primary information
ID	1425
ThPP ID	Th1071
Therapeutic Peptide/Protein Name	Pancrelipase
Sequence	Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	131125.6
Chemical Formula	C5850H8902N1606O1739S49
Isoelectric Point	9.44
Hydrophobicity	N.A.
Melting Point (℃)	48-53
Half Life	Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description	Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease	For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics	Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action	The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity	Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism	Pancrelipase acts locally, so there is minimal metabolism.
Absorption	Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution	N.A.
Clearance	Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories	Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	PERTZYE
Company	Digestive care US, Inc.
Brand Discription	PERTZYE is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived fromÂ porcineÂ pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, proteases, and amylases.
Prescribed for	PERTZYE (pancrelipase) is indicated for the treatment of exocrinepancreatic insufficiencyÂ due toÂ cystic fibrosisÂ or other conditions.
Chemical Name	N.A.
Formulation	Each PERTZYE delayed-release capsule for oral administration contains bicarbonatebufferedÂ enteric-coatedÂ microspheres ranging in size from 0.8 â€“ 2.2 mm in diameter.8,000 USP units of lipase; 28,750 USP units of protease; 30,250 USP units of amylase. it also contains odium bicarbonate, sodium carbonate, cellulose acetate phthalate, sodium starch glycolate, diethyl phthalate, ursodiol, polyvinylpyrrolidone, and talc and are contained in hard gelatin capsules.
Physcial Appearance	Pancrelipase is a beige-white amorphous powder. It is miscible in water and practically insoluble or insoluble in alcohol and ether PERTZYE delayed-release capsule
Route of Administration	Oral route
Recommended Dosage	Enzyme dosing should begin with 500 lipase units/kg of body weight per meal for those older than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Contraindication	None
Side Effects	The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy,hyperuricemiaÂ and allergic reactions
Useful Link	http://www.rxlist.com/pertzye-drug.htm
PubMed ID	28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure	Th1071 (View) or (Download)

Primary information
ID	1426
ThPP ID	Th1071
Therapeutic Peptide/Protein Name	Pancrelipase
Sequence	Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	131125.6
Chemical Formula	C5850H8902N1606O1739S49
Isoelectric Point	10.44
Hydrophobicity	N.A.
Melting Point (℃)	48-54
Half Life	Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description	Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease	For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics	Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action	The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity	Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism	Pancrelipase acts locally, so there is minimal metabolism.
Absorption	Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution	N.A.
Clearance	Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories	Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	ULTRASE
Company	Axcan Pharma
Brand Discription	ULTRASE (pancrelipase) Capsules are orally administered and contain 250 mg of enteric-coated microspheres ofÂ porcineÂ pancreaticÂ enzymeconcentrate, predominantly pancreatic lipase,Â amylase, andÂ protease.
Prescribed for	ULTRASE (pancrelipase) Capsules are indicated for patients with partial or complete exocrine pancreatic insufficiency caused by cystic fibrosis, Chronic pancreatitis due to alcohol, Obstruction, Other pancreatic disease, Poor mixing
Chemical Name	N.A.
Formulation	Each ULTRASE (pancrelipase) Capsule contains 4500 USP units of lipase; 25000 USP units of protease; 20000 USP units of amylase. It contains povidone, talc, sugar, methacrylic acid copolymer (Type C), triethyl citrate, simethicone emulsion.
Physcial Appearance	Capsules Enteric-Coated Microspheres
Route of Administration	Oral route
Recommended Dosage	Initial dosing of pancreatic enzyme supplements should begin with 500 lipase U/kg/meal using enteric-coated microsphere products.
Contraindication	Pancrelipase capsules are contraindicated in patients known to be hypersensitive to porkÂ protein. Pancrelipase capsules are contraindicated in patients withÂ acute pancreatitisÂ or withÂ acuteÂ exacerbations ofÂ chronicpancreaticÂ diseases.
Side Effects	Â Extremely high doses ofÂ exogenouspancreaticÂ enzymesÂ have been associated with hyperuricosuria andhyperuricemia,
Useful Link	http://www.rxlist.com/ultrase-drug.htm
PubMed ID	28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure	Th1071 (View) or (Download)

Primary information
ID	1427
ThPP ID	Th1071
Therapeutic Peptide/Protein Name	Pancrelipase
Sequence	Pancreatic alpha amylase: QYSPNTQQGRTSIVHLFEWRWVDI view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	131125.6
Chemical Formula	C5850H8902N1606O1739S49
Isoelectric Point	11.44
Hydrophobicity	N.A.
Melting Point (℃)	48-55
Half Life	Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so ther
Description	Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa and Viokace.
Indication/Disease	For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa), chronic pancreatitis (Viokace in combination with a proton pump inhibitor), and pancreatectomy (Viokace in combination with a proton pump inhibitor)
Pharmacodynamics	Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.
Mechanism of Action	The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.
Toxicity	Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.
Metabolism	Pancrelipase acts locally, so there is minimal metabolism.
Absorption	Pancrelipase is not significantly absorbed from the gastrointestinal tract.
Volume of Distribution	N.A.
Clearance	Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.
Categories	Gastrointestinal Agents and Enzyme Replacement Agents
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Dietary fat,Dietary protein,Dietary starch
Information of corresponding available drug in the market
Brand Name	ZENPEP
Company	Aptalis Pharma US, Inc.
Brand Discription	ZENPEP is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived fromÂ porcineÂ pancreatic glands. Pancrelipase contains multiple enzyme classes, including porcine-derived lipases, proteases, and amylases.
Prescribed for	ZENPEP (pancrelipase) is indicated for the treatment of exocrinepancreatic insufficiencyÂ due toÂ cystic fibrosisÂ or other conditions.
Chemical Name	N.A.
Formulation	Each capsule for oral administration containsÂ enteric-coatedÂ beads (1.8-1.9mm for 3,000 and 5,000 USP units of lipase, 2.2-2.5mm for 10,000, 15,000, 20,000, 25,000, and 40,000 USP units of lipase). ZENPEP include colloidal silicon dioxide, croscarmellose sodium, hydrogenated castor oil, hypromellose phthalate, magnesium stearate, microcrystalline cellulose, talc, and triethyl citrate and are contained in hypromellose capsules. The imprinting red ink on the 3,000 capsules strength contains, antifoam DC 1510, industrial methylated spirit, iron oxide red C.I. 77491-E172, n-butyl alcohol, shellac and soya lecithin.
Physcial Appearance	Delayed-Release Capsules
Route of Administration	Oral route
Recommended Dosage	Enzyme dosing should begin with 500 lipase units/kg of body weight per meal for those older than age 4 years to a maximum of 2,500 lipase units/kg of body weight per meal (or less than or equal to 10,000 lipase units/kg of body weight per day), or less than 4,000 lipase units/g fat ingested per day.
Contraindication	None
Side Effects	The most serious adverse reactions reported with different pancreatic enzyme products of the same active ingredient (pancrelipase) that are described elsewhere in the label include fibrosing colonopathy,hyperuricemiaÂ and allergic reactions
Useful Link	http://www.rxlist.com/zenpep-drug.htm
PubMed ID	28099252, 27560634, 26748629, 26726093, 26709820, 26495784, 26495776, 26150571, 26036459
3-D Structure	Th1071 (View) or (Download)